Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AlyveRx vs Aspen

AlyveRx
Graded #103

Higher grade

vs+12.100000000000001
Aspen
Graded #372

Lower grade

The verdict

AlyveRx takes it — 70.5/100 to 58.4/100.

AlyveRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AlyveRx (Alyve, Inc.) is a US online telehealth platform connecting patients with licensed providers for GLP-1 weight loss care, no insurance required, with free discreet delivery.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAlyveRx +42
69
27
Dose & formulationAlyveRx +32
96
64
Clinical oversightAspen +9
71
80
Labs & monitoringEven
52
52
FulfillmentAspen +30
64
94
Contract termsAlyveRx +8
55
47
AlyveRx · left barAspen · right bar

The numbers

MetricAlyveRxAspen
WeighScore70.5/10058.4/100
GradeCC
Scorecard rank#103#372
Semaglutide$183/mo (all doses, compounded)$279/mo (3-month plan, compounded)
Tirzepatide$249/mo (all doses, compounded)$399/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
AlyveRx

Graded #103 · C

Strengths

  • Offers compounded semaglutide and tirzepatide as both injections and needle-free sublingual drops for people who dislike needles
  • Transparent monthly pricing shown upfront, no insurance required, and free discreet delivery
  • Also carries brand-name Ozempic, Wegovy, and Mounjaro through its provider network

Where it loses points

  • Does not publicly name its dispensing pharmacy or display a LegitScript seal, so third-party accreditation is unverified
  • Sublingual GLP-1 absorption relies on the company proprietary PermeAct technology and is not FDA-reviewed for weight loss
  • State availability is not published on the site
Aspen

Graded #372 · C

Strengths

  • LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
  • Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
  • Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
  • Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
  • Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
  • Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
  • The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
  • Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard